Biological assay challenges from compound solubility: strategies for bioassay optimization

Area of Science:

• Medicinal Chemistry
• Biochemistry
• Pharmacology

Background:

• Compound solubility in buffers and dimethyl sulfoxide (DMSO) is critical for drug discovery.
• Many valuable lead compounds exhibit poor solubility, complicating biological assessments.
• Low solubility can lead to underestimated activity, reduced high-throughput screening (HTS) hit rates, and unreliable data.

Purpose of the Study:

• To highlight the challenges posed by low compound solubility in bioassays.
• To present strategies for optimizing bioassays to accommodate compounds with poor solubility.
• To emphasize the importance of addressing solubility early in the drug discovery process.

Main Methods:

• Reviewing common issues arising from poor compound solubility in various assay formats.
• Identifying and discussing practical strategies for improving compound solubilization and handling.
• Emphasizing the integration of solubility considerations into HTS library design and assay development.

Main Results:

• Low solubility negatively impacts assay performance, including structure-activity relationship (SAR) determination and in vitro ADME-Tox testing.
• Effective strategies include early solubility screening, optimized DMSO stock management, and appropriate dilution protocols.
• Addressing solubility issues enables more accurate evaluation of potential drug candidates.

Conclusions:

• Overcoming solubility challenges is essential for the successful identification and development of novel therapeutics.
• Proactive management of compound solubility ensures reliable bioassay data and efficient drug discovery.
• Chemical optimization of solubility can be addressed in later stages once promising pharmacophores are identified.